Video

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

Author(s):

Oliver Sartor, MD

In Partnership With:

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 has a unique mechanism of action in that it binds to hydroxyapatite and radiates the tumor microenvironment. Though the mechanism of action is not yet fully understood by researchers, Sartor says it could have pro-immune effect, anti-angiogenic effect, and/or a microenvironmental effect on tumors.

Grade 3/4 thrombocytopenia is one treatment-related adverse event associated with radium-223. Less common and lower grade adverse events include anemia, leukopenia, diarrhea, and fatigue, he says.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
July 11th 2024

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

S. Lindsey Davis, MD, oncologist, University of Colorado Cancer Center; associate professor, medicine-medical oncology, University of Colorado Anschutz Medical Campus
July 5th 2024

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

Steffen Heeger, MD, MSc
July 3rd 2024

FDA Grants Fast Track Designation to 225Ac-FL-020 for mCRPC